arterioscope is a spin-off from Graz University of Technology and a deep-tech software company building an AI-powered digital biomarker platform for cardiovascular disease. We develop and validate machine-learning models that extract clinically relevant cardiac biomarkers and risk signals from ECG and PPG data, enabling scalable, non-invasive cardiovascular phenotyping. Our technology is designed to support biotech and pharma companies in clinical research by generating robust, biomarker-grade cardiovascular insights from standard biosignals, without requiring dedicated hardware or hospital infrastructure. The platform is modular, device-agnostic, and protected by granted and pending patents in Europe and the United States. arterioscope is currently preparing market entry and regulatory certification while raising its seed round to advance clinical validation and commercialization. Let’s talk.